This Is MS Multiple Sclerosis Community: Knowledge & Support

In patients with relapsing-remitting multiple sclerosis (MS), interrupting treatment with natalizumab (Tysabri, Biogen) often leads to relapse, a new study shows.

The findings "confirm a high rate of recurrence" of magnetic resonance imaging (MRI)-defined and clinical MS disease activity starting at approximately week 12, during a 24-week interruption of natalizumab therapy, a study team notes.

"Clearly, the risk of return of disease activity during treatment interruption is notable, even with the alternative immunomodulatory therapies used in this study," Robert J. Fox, MD, neurologist and medical director of the Mellen Center for MS at the Cleveland Clinic, Ohio, and leader of the study team, said in his presentation here at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis